Organoids can be derived from patient-derived normal adult or tumor tissues (patient-derived organoids, PDOs) or pluripotent stem cells, including human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs). Isolation and expansion of resident stem cells are critical for self-renewal of tissue-derived organoids, while stem cell differentiation drives pluripotent-stem-cell-derived organoid formation. Additional key factors include qualified batches of GFR-reduced Matrigel matrix, standardized passaging techniques, and high-quality culture media and reagents. OgCelix provides fully validated Organoid Culture Media and tissue-specific dissociation reagents to ensure reproducible organoid generation.

One of the major challenges in organoid culture is the current reliance on animal-derived extracellular matrices (ECMs), such as Matrigel®. Synthetic matrices, including hybrid polyethylene glycol (PEG)-based hydrogels or engineered collagen scaffolds combined with defined laminins, may better support the organoid microenvironment and can be customized for specific tissues or applications._x000D_ _x000D_ Although organoids can closely recapitulate the structure and function of their tissue of origin, most organoid systems lack additional cell types present in vivo, such as endothelial cells, immune cells, and stromal cells. This limitation can affect their ability to fully model physiological complexity in vitro. Emerging organ-on-a-chip technologies may help address this issue, as they enable the integration of multiple cell types to better mimic certain aspects of human physiology.

Yes. Within a suitable range, studies (e.g., Calandrini et al., 2022) have shown that the growth rate and size of organoids are positively correlated with the number of cells seeded. Seeding at an appropriate density enhances organoid formation efficiency. However, excessively high seeding density may lead to increased cell death in the core region of the Matrigel dome._x000D_ Calandrini C, Drost J, et al. Normal and tumor-derived organoids as a drug-screening platform for tumor-specific drug vulnerabilities. STAR Protoc. 2022;3(1):101079.

Organoids can be generated from a wide range of epithelial tissues, including both healthy and diseased intestine, liver, pancreas, breast, and lung, either directly from patient- or animal-derived tissues, or through directed differentiation of pluripotent stem cells. Unlike other patient-derived 3D models, organoids form tissue-like structures that closely recapitulate the histological architecture of the original organ._x000D_ _x000D_ Organoids exhibit long-term expansion capacity without transformation, while maintaining genetic and phenotypic stability and preserving key biological and functional characteristics of the source tissue. The presence of epithelial stem cells supports continuous growth and differentiation into multiple cell types found in the native tissue. In addition, organoid cultures can be scaled and adapted for high-throughput applications, making them a powerful in vitro platform for drug discovery, diagnostics, and patient stratification.

Yes. Organoids can be temporarily stored at low temperatures (e.g., 4 ℃) for short-term use, while long-term storage relies on cryopreservation with type-specific optimized cryopreservation media. Most patient-derived organoids can be successfully cryopreserved. However, highly terminally mature iPSC‑derived organoids such as cerebral organoids show poor post-thaw viability after cryopreservation. Pretreatment with a ROCK inhibitor (e.g., Y-27632) before freezing is recommended to improve post-thaw cell viability. All patient-derived organoids supplied by OgCelix are cryopreserved using validated protocols, achieving post-thaw viability of over 80% for rapid culture recovery.

Yes. Organoids are highly suitable for studying a broad range of human diseases, including cancer, monogenic genetic disorders, and metabolic diseases. They faithfully recapitulate patient-specific pathological features and tissue architecture, serving as powerful tools for disease mechanism exploration and personalized drug screening. However, limitations exist such as insufficient vascularization and incomplete immune/stromal cell integration, restricting their application in systemic disease modeling.

Organoids can be analyzed by immunocytochemistry (ICC) or immunohistochemistry (IHC) using whole-mount staining or paraffin embedding and sectioning techniques. It is essential to use antibodies that have been validated for organoid-based applications.

Generally, organoids can be maintained and expanded in vitro for several weeks to years, with tumor-derived organoids capable of near-indefinite passaging. Their longevity is mainly determined by tissue origin, donor health status, stem cell potency, and culture system optimization. To ensure long-term expansion without genomic instability, marker expression and karyotype analysis are recommended every 5-10 passages. Preserving resident stem cell populations relies on high-potency growth factors and tissue-specific validated culture media.